Visby Medical’s personal PCR device for COVID-19 testing gets EUA
Oct. 23, 2020—The FDA has issued an emergency use authorization for Visby Medical’s single-use personal PCR device, a rapid test for detecting COVID-19.
Webinars and Sponsored Roundtables — Register Now
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
Lenco Lab using CGM LIS in COVID-19 testing program
Oct. 22, 2020—CompuGroup Medical recently reported that it contributed to Lenco Diagnostic Laboratory launching its COVID-19 testing program in Brooklyn, NY.
FDA issues EUA for saline oral rinse COVID test
Oct. 15, 2020—OralDNA Labs announced that the FDA has issued an amended emergency use authorization for the OraRisk COVID-19 RT-PCR test, allowing testing from a saline oral rinse collection.
Beckman’s SARS-CoV-2 IgM antibody test gets EUA
Oct. 12, 2020—Beckman Coulter announced its Access SARS-CoV-2 immunoglobulin M assay has received emergency use authorization from the FDA.
GenMark ePlex Respiratory Pathogen Panel 2 receives EUA
Oct. 9, 2020—GenMark Diagnostics received FDA emergency use authorization for its ePlex Respiratory Pathogen Panel 2.
Aptima SARS-CoV-2 assay to include testing of asymptomatic people
Oct. 7, 2020—Hologic’s Aptima SARS-CoV-2 assay, which initially received emergency use authorization from the FDA in May, is now authorized for testing people without symptoms or other reasons to suspect COVID-19 infection.
CompuGroup Medical hosts virtual user conference
Oct. 6, 2020—CompuGroup Medical US will hold its annual CGM LABDAQ User Conference virtually, starting Oct. 6.
Beckman Coulter Access IL-6 test gets EUA
Oct. 6, 2020—Beckman Coulter has received emergency use authorization for its Access Interleukin-6 assay from the FDA.
Cepheid SARS-CoV-2, flu A/B, RSV test gets EUA
Oct. 5, 2020—Cepheid received emergency use authorization from the FDA for its Xpert Xpress SARS-CoV-2/Flu/RSV, a rapid molecular diagnostic test for qualitative detection of the viruses that cause COVID-19, flu A, flu B, and RSV infections from a single patient sample.
Technopath introduces QC data management solution
Oct. 2, 2020—Technopath Clinical Diagnostics introduced IAMQC Infinity for the management of overall quality control and proficiency testing.